An open-label phase II trial (NCT05526989) is evaluating the combination of niraparib, a Poly (ADP-ribose) polymerase (PARP) inhibitor, and dostarlimab, an anti-PD-1 antibody, in patients with stage III/IV PSCC refractory to platinum-based chemotherapy. This evidence concerns the gene PDCD1 and squamous cell carcinoma of penis.